Compare Expedia Group Inc (EXPE) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs GSK plc — how do they compare? Expedia Group Inc trades at $266.65 (market cap $32.06B), while GSK plc trades at $52.39 (market cap $101.34B). The key difference: GSK plc is far larger — about 3.2× Expedia Group Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| EXPE | GSK | |
|---|---|---|
Market Cap | $32.06B | $101.34B |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $61.18 |
52-Week Low | $178.06 | $36.20 |
Enterprise Value | $30.97B | $121.95B |
Dividend Yield | 0.66% | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $266.28, showing modest daily gains of 0.24%. The stock exhibits a bullish technical signal, supported by strong earnings beats in recent quarters and robust revenue growth from $11.7B in 2022 to $14.7B in 2025. The company maintains high profitability with a 90.27% gross margin and recently announced a strategic partnership with Allegiant Travel Company, expanding its online travel agency network.
The investment outlook is positive with analyst consensus at $292.09, representing 9.7% upside potential. Key opportunities include continued travel sector growth and operational efficiency gains from recent technology investments. Primary risks involve macroeconomic sensitivity affecting travel demand and competitive pressures in the online travel market. The company's strong cash flow generation supports shareholder returns through dividends and potential buybacks.
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
